Physician profile
Christopher D Parrish
NPI 1801042239
$1,225.16
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $208 · 2021: $175 · 2022: $116 · 2023: $86.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.29 | 2019-2023 | Jardiance, Tradjenta |
| Amgen INC. | $210.32 | 2019-2020 | |
| Abbvie INC. | $172.49 | 2019-2023 | |
| Novo Nordisk INC | $96.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $83.74 | 2019-2021 | |
| Allergan, INC. | $72.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.83 | 2019-2020 | |
| Pfizer INC. | $41.23 | 2019-2020 | |
| Lilly USA, LLC | $27.79 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.12 | 2022-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $20.93 | 2019 | |
| Abbott Laboratories | $19.85 | 2019 | |
| Glaxosmithkline, LLC. | $19.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.38 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.